Abacavir/lamivudine
Combination of | |
---|---|
Abacavir | Nucleotide analogue reverse transcriptase inhibitor |
Lamivudine | Nucleotide analogue reverse transcriptase inhibitor |
Clinical data | |
Trade names | Kivexa, Epzicom |
MedlinePlus | a696011 |
Pregnancy category |
|
Legal status |
|
Routes of administration |
Oral |
Identifiers | |
CAS Number | 852337-16-7 |
ATC code | J05AR02 (WHO) |
PubChem | CID: 5273759 |
NIAID ChemDB | 225604 |
(what is this?) (verify) |
Abacavir/lamivudine (INNs) is a combination drug for the treatment of HIV infection.[1][2] It is marketed as Kivexa in most countries except for the United States, where it is branded as Epzicom.[3] It is a fixed dose combination of a certain crystal form of lamivudine (3TC, Epivir) and the hemisulphate salt of abacavir (ABC, Ziagen).
Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTI).
It was approved by the FDA on August 2, 2004. It is marketed by ViiV Healthcare. As of 2015 the cost for a typical month of medication in the United States is more than 200 USD.[4]
Legal challenges
Teva Pharmaceuticals and Lupin Ltd both filed abbreviated new drug applications (ANDAs) relating to the treatments of HIV using various combinations of abacavir, lamivudine and AZT, and challenging various patents. In 2013 the US District Court for the District of Delaware upheld the validity of a patent covering Epzicom and Tizivir. Other matters were subject to appeal or litigation as of 20 November 2014.[5]
See also
- Abacavir/lamivudine/zidovudine, tradename Trizivir
- Abacavir/dolutegravir/lamivudine, tradename Triumeq
References
<templatestyles src="Asbox/styles.css"></templatestyles>
- Drugs that are a combination of chemicals
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Fixed dose combination (antiretroviral)
- World Health Organization essential medicines
- Antiinfective agent stubs